Cargando…
Can metronomic chemotherapy be an alternative to sorafenib in advanced hepatocellular carcinoma?
Autor principal: | Kim, Do Young |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association for the Study of the Liver
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497668/ https://www.ncbi.nlm.nih.gov/pubmed/28669140 http://dx.doi.org/10.3350/cmh.2017.0107 |
Ejemplares similares
-
Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments
por: Suzuki, Hiroyuki, et al.
Publicado: (2021) -
A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function
por: Yang, Hyun, et al.
Publicado: (2017) -
Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma
por: Han, Sojung, et al.
Publicado: (2020) -
Metronomic Capecitabine in Patients With Hepatocellular Carcinoma Unresponsive to or Ineligible for Sorafenib Treatment: Report of Two Cases
por: Marinelli, Sara, et al.
Publicado: (2013) -
Low‐dose metronomic chemotherapy improves tumor control in nasopharyngeal carcinoma
por: Chen, Yu‐Pei, et al.
Publicado: (2022)